GlassScriptPhysician profile
Aaron Fond
NPI 1952842213
$2,104.55
in general payments reported to CMS, 2019-2025
18 companies · $1,089 in 2025
The $1,089 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $146 · 2024: $869 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $320.62 | 2024-2025 | Voquezna |
| Genzyme Corporation | $311.55 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $244.76 | 2024-2025 | Entyvio |
| Pfizer INC. | $179.71 | 2024-2025 | |
| Abbvie INC. | $173.67 | 2024-2025 | |
| Qol Medical, LLC | $167.72 | 2024-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $148.92 | 2024-2025 | Stelara, Tremfya |
| Enterra Medical, INC. | $146.44 | 2023 | |
| Intercept Pharmaceuticals, INC. | $103.33 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.39 | 2025 | Xifaxan |
| Ardelyx, INC. | $64.28 | 2025 | Ibsrela |
| Novo Nordisk INC | $39.71 | 2025 | Wegovy |
| Merck Sharp & Dohme LLC | $32.52 | 2024 | Dificid |
| Celltrion USA INC. | $26.68 | 2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $25.04 | 2024 | Dupixent |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $24.18 | 2024 | Iqirvo |
| Exact Sciences Corporation | $15.37 | 2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $14.66 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Fond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.